Evidence map›Paper›PMID 34722160›Full record

ArticleJournal of clinical & translational endocrinology2021

COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes.

Kelly Mason, Sana Hasan, Amy Darukhanavala, Katherine Kutney

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Infection with SARS-CoV-2 can cause pancreatic impairment.Signal transduction and targeted therapy · 2024
    Article
  5. Article
  6. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Kelly MasonUniversity of Virginia, Department of Pediatric Endocrinology, PO Box 800386, Charlottesville, VA 22908, USA.
Sana HasanCleveland Clinic, Endocrinology and Metabolism Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Amy DarukhanavalaUMass Medical Center, Department of Pediatric Endocrinology, 55 Lake Avenue North, Worcester, MA 01655, USA.
Katherine KutneyUniversity Hospitals Cleveland Medical Center/Rainbow Babies and Children's Hospital, Department of Pediatric Endocrinology, 11100 Euclid Ave, Suite 737, Cleveland, OH 44106, USA.
Cleveland Clinic · USRainbow Babies & Children's Hospital · USUMass Memorial Health Care · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel SARS-CoV-2 coronavirus (COVID-19) has become a global health crisis since its initial outbreak in Wuhan, China in December 2019. On January 30, 2020, the WHO recognized the COVID-19 outbreak as a Public Health Emergency, and on March 11, 2020, it was declared a pandemic. Although all age groups have been affected, patients with cystic fibrosis (CF) and patients with type 1 or type 2 diabeteshave been categorized as highly vulnerable to SARS-CoV-2 infection. Thus far, studies have found that the incidence of SARS-CoV-2 in the CF population is lower than the general population. We review the underlying protective mechanisms which may reduce inflammation and lung damage in CF patients, thus decreasing their risk of severe COVID-19. While the effect of SARS-CoV-2 in those with

Indexed as

ACE2COVID-19Cystic fibrosisCystic fibrosis-related diabetesDiabetesSARS-CoV-2

Identifiers

PMID34722160
PMCPMC8545686
OpenAlexW3209458113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.